Perceived barriers to career progression in the headache field: A global web-based cross-sectional survey
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 966 KB, PDF-dokument
Background: It is well recognized that underrepresented and minoritized groups do not have the same career opportunities. However, there are limited data on the range and specifics of potential barriers that withhold people in headache medicine and science from reaching their full potential. Moreover, people from different geographical regions often perceive different challenges. We aimed to identify world-wide perceived career barriers and possibilities for promoting equality amongst professionals in the headache fields. Methods: A cross-sectional online survey was conducted among professionals in the field of headache globally. The questions of the survey were aimed at assessing perceived career barriers in four domains: professional recognition, opportunities in scientific societies, clinical practice, and salary and compensation. Perceived mentorship was also assessed. Results: In total 580 responders completed the survey (55.3% women). Gender was the most important perceived barrier in almost all domains. Additionally, country of birth emerged as an important barrier to participation in international scientific societies. Career barriers varied across world regions. Conclusion: It is essential that longstanding and ongoing disparities by gender and country of origin for professionals in the headache field are globally acknowledged and addressed in areas of recruitment, retention, opportunities, mentor- and sponsorships, and advancement.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Cephalalgia |
| Vol/bind | 42 |
| Udgave nummer | 14 |
| Sider (fra-til) | 1498-1509 |
| Antal sider | 12 |
| ISSN | 0333-1024 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a granted project proposal by the International Headache Society.
Funding Information:
IdB reports independent support from the International Retinal Research Foundation and Dutch Heart Foundation. AA reports consultancy or industry support from Novartis, Eli-Lilly and Teva. RBHS reports a research grant from Amgen. BB has nothing to disclose. DCB has received research funding from the US Food and Drug Administration, the National Headache Foundation and Amgen. She has also received consulting fees from Amgen, Allergan/Abbvie, Lilly, Lundbeck and Teva. CT has received honoraria as a consultant and speaker for Amgen, Allergan/AbbVie, Almirall, Biohaven, Eli Lilly, Lundbeck, Medscape, Novartis and Teva Pharmaceuticals. Her research group has received research grants from Allergan/AbbVie, EraNet Neuron, Italia Ministry of Health. Her Institution has received payment for clinical trials from AbbVie, Eli Lilly, Lundbeck, Novartis and Teva Pharmaceuticals. RHJ has given lectures for Pfizer, Eli-Lilly, Merck, TEVA, Novartis, Lundbeck and Allergan, is investigator in clinical trials with Eli-Lilly, Novartis and Lundbeck, is director of Danish Headache Center, Lifting The Global Burden of Headache and Founder of Master of Headache Disorders at University of Copenhagen and has received research funding from University of Copenhagen, Rigshospitalet, Lundbeck Foundation, The Medical Society in Copenhagen, NovoNordisk Foundation and Tryg Foundation. PPR has received honoraria as a consultant and speaker for Amgen, Allergan/AbbVie, Almirall, Biohaven, Chiesi, Eli Lilly, Lundbeck, Medscape, Neurodiem, Novartis and Teva Pharmaceuticals. Her research group has received research grants from Allergan/AbbVie, AGAUR, la Caixa foundation, EraNet Neuron, Instituto Investigación Carlos III, MICINN, Novartis, PERIS, RIS3CAT, Teva Pharmaceuticals; and has received funding for clinical trials from AbbVie, Biohaven, Electrocore, Eli Lilly, Lundbeck, Novartis and Teva Pharmaceuticals. GMT reports independent support from the Dutch Research Council, and the Dutch Hearth and Brain Foundations, Dioraphte and IRRF, she reports consultancy or industry support from Novartis, Lilly and Teva, Allergan (Abbvie), Lundbeck.
Publisher Copyright:
© International Headache Society 2022.
ID: 322656757